FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1290-1291 November 9, 1995 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Soumerai, S. B. PubMed Citation

To the Editor: Much of the concern voiced about drug-utilization review by Drs. Soumerai and Lipton (June 15 issue)¹ — about the lack of proof that this process is cost effective, the lack of attention paid to the underuse of effective medications, and the inadequacy of the criteria used in screening — is on target. This concern also suggests a substantial disconnectedness between the research community and those dealing with drug-utilization review in an operational environment. The rush to managed care and the passage of the Omnibus Budget Reconciliation Act of 1990 resulted in the widespread implementation of drug-utilization review . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Schiff, G. D., Klass, D., Peterson, J., Shah, G., Bates, D. W. (2003). Linking Laboratory and Pharmacy: Opportunities for Reducing Errors and Improving Care. Arch Intern Med 163: 893-900 [Abstract] [Full Text]